Preclinical Auger and gamma radiation dosimetry for fluorodeoxyuridine-enhanced tumour proliferation scintigraphy with [123I]iododeoxyuridine

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 2, 2003, Pages 239-246

  Buchegger, Franz ^a,b   Vieira, Jean Marc ^b   Blaeuenstein, Peter ^c   Dupertuis, Yves Marc ^b   Schaffland, Andreas Oliver ^a   Grannavell, Carine ^a   De Tribolet, Nicolas ^b   Slosman, Daniel Olivier ^b   Delaloye, Angelika Bischof ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

Auger radiation; Dosimetry; Fluorodeoxyuridine; Proliferation scintigraphy; 123I Iododeoxyuridine

Indexed keywords

FLOXURIDINE; IDOXURIDINE I 123; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUGER RADIATION; CALCULATION; CONTROLLED STUDY; DOSIMETRY; DRUG DISTRIBUTION; GAMMA RADIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; INJECTION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; RADIATION ABSORPTION; RADIATION DOSE; RADIATION EXPOSURE; RADIOACTIVITY; TUMOR SCINTISCANNING;

EID: 0037501313     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-1049-1     Document Type: Article

References (34)

1. Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, O'Sullivan F, Krohn KA. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res 1999; 59:615-621.
2. 124I]iododeoxyuridine. Cancer Res 2000; 60:624-635.
3. 76Br]Bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice. Nucl Med Biol 1999; 26:673-679.
4. 76Br]Bromodeoxyuridine PET in tumor-bearing animals. Nucl Med Biol 2001; 28:51-57.
5. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987; 109:78-89.
6. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4:1334-1336.
7. 11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol 1995; 22:783-789.
8. Panyutin IG, Winters TA, Feinendegen LE, Neumann RD. Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for anti-gene radiotherapy. Q J Nucl Med 2000; 44:256-267.
9. 125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors. Eur J Cancer 1996; 32A:1603-1608.
10. 125I]iod-2′-deoxyuridine in mammalian cells following treatment with 5-fluoro-2′-deoxyuridine. J Nucl Biol Med 1991; 35:167-173.
11. Lawrence TS, Davis MA, McKeever PE, Maybaum J, Stetson PL, Normolle DP, Ensminger WD. Fluorodeoxyuridine-mediated modulation of iododeoxyuridine incorporation and radiosensitization in human colon cancer cells in vitro and in vivo. Cancer Res 1991; 51:3900-3905.
12. Dupertuis YM, Vazquez M, Mach J-P, de Tribolet N, Pichard C, Slosman DO, Buchegger F. Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine. Cancer Res 2001; 61:7971-7977.
13. Wilson WL, Bisel HF, Krementz ET, Lien RC, Prohaska JV. Further clinical evaluation of 2′-deoxy-5-fluorouridine (NSC-27640). Cancer Chemother Rep 1967; 51:85-90.
14. Serlin O, Wolkoff JS, Amadeo JM, Keehn RJ. Use of 5-fluorodeoxyuridine (FUDR) as an adjuvant to the surgical management of carcinoma of the stomach. Cancer 1969; 24:223-228.
15. Humm JL, Howell RW, Rao DV. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1994; 21:1901-1915.
16. 125I and the problem of quality factor. Radiat Environ Biophys 1987; 26:181-188.
17. 125I]iodo-2′-deoxyuridine. Radiat Res 1989; 118: 532-544.
18. 125I compared with that of densely ionising alpha-particles. Lancet 1989; 2:650-653.
19. Rao DV, Narra VR, Howell RW, Lanka VK, Sastry KS. Induction of sperm head abnormalities by incorporated radionuclides: dependence on subcellular distribution, type of radiation, dose rate, and presence of radioprotectors. Radiat Res 1991; 125:89-97.
20. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N, Cavenee WK. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 1994; 54:649-652.
21. Foulon CF, Adelstein SJ, Kassis AI. Kit formulation for the preparation of radiolabeled iododeoxyuridine by demetallation. J Nucl Med 1996; 37:1S-3S.
22. Howell RW. Radiation spectra for Auger-electron emitting radionuclides: report No. 2 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1992; 19:1371-1383.
23. Wang H, Oliver P, Nan L, Wang S, Wang Z, Rhie JK, Zhang R, Hill DL. Radiolabeled 2′-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2′-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) as tumor- imaging agents in mice. Cancer Chemother Pharmacol 2002; 49:419-424.
24. Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill AB, Wessels B. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys 2000; 27:2150-2164.
25. Schofield R, Dexter TM, Lord BI, Testa NG. Comparison of haemopoiesis in young and old mice. Mech Ageing Dev 1986; 34:1-12.
26. 3H-TdR. Exp Hematol 1982; 10:514-523.
27. Buchegger F, Chalandon Y, Pelegrin A, Hardman N, Mach JP. Bone marrow dosimetry in rats using direct tissue counting after injection of radio-iodinated intact monoclonal antibodies or F(ab′)2 fragments. J Nucl Med 1991; 32:1414-1421.
28. Goddu SM, Howell RW, Rao DV. Calculation of equivalent dose for Auger electron emitting radionuclides distributed in human organs. Acta Oncol 1996; 35:909-916.
29. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37:538-546.
30. ICRP publication 53: Radiation dose to patients from radiopharmaceuticals. Ann ICRP 1987; 18:259-280.
31. ICRP publication 80: Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP 1998; 28:p118.
32. 18F]Fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62:3331-3334.
33. Haines GA, Hendry JH, Daniel CP, Morris ID. Increased levels of comet-detected spermatozoa DNA damage following in vivo isotopic- or X-irradiation of spermatogonia. Mutat Res 2001; 495:21-32.
34. Hoyes KP, Nettleton JS, Lawson RS, Morris ID. Transferr-independent uptake and dosimetry of Auger-emitting diagnostic radionuclides in human spermatozoa. J Nucl Med 1998; 39:895-899.